03 November 2020
: Case report 
Efficacy of Hyperthermia in Treatment of Recurrent Metastatic Breast Cancer After Long-Term Chemotherapy: A Report of 2 Cases
Unusual clinical course, Unusual setting of medical care
Hirozumi Sawai1ABCDEF*, Masaaki Kurimoto1ABCD, Yuka Suzuki2BCD, Yoshimi Yamaguchi2BCD, Akemi Murata2BCD, Enami Suganuma2BCD, Kazuya Yamamoto2ABCD, Hiromasa Kuzuya1BCDF, Shuhei Ueno1BCDF, Shuji Koide1ABCF, Hajime Koide1BCDF, Atsushi Kamiya1ABCEDOI: 10.12659/AJCR.926647
Am J Case Rep 2020; 21:e926647
Figure 5. Detailed clinical history and the notable trend of tumor markers since January 2019 in Case 2. AI – aromatase inhibitor; Bv – bevacizumab; EC – epirubicin hydrochloride+cyclophosphamide hydrate; EM – eribulin mesylate; FUL – fulvestrant; GEM – gemcitabine; PTX – paclitaxel; RF-HT – radiofrequency hyperthermia; TAM – tamoxifen; XC – capecitabine+cyclophosphamide hydrate; CEA – carcinoembryonic antigen (<5.0 ng/mL); CA15-3 – cancer antigen 15-3 (<25 U/mL).